Mizuho analyst Salim Syed raised the firm’s price target on Biogen to $340 from $315 and keeps a Buy rating on the shares. The analyst updated the firm’s model post the Q1 results. The analyst now estimates Ocrevus worldwide peak sales of $8B in 2025, up from $7.5B previously.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on BIIB: